An update on heparins at the beginning of the new millennium

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 3 SUPPL. 1, 2000, Pages 5-21

  Fareed, J ^a   Hoppensteadt, D A ^a   Bick, R L ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Heparin; Heparin omimetics; LMW heparin; Pentasaccharide; Tissue factor pathway inhibitor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ARDEPARIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; CELL ADHESION MOLECULE; CILOSTAZOL; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HEPARIN DERIVATIVE; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; THROMBIN; TIROFIBAN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; BLOOD TRANSFUSION; CARDIOVASCULAR SURGERY; CONFERENCE PAPER; DEPOLYMERIZATION; DRUG CHOICE; DRUG EFFECT; DRUG FORMULATION; DRUG INDICATION; HEPARINIZATION; HUMAN; MEDIATOR RELEASE; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS;

CARDIOLOGY; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HEPARIN LYASE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERVENTION STUDIES; THROMBOSIS;

EID: 0033816136     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Newer approaches to the pharmacologic management of acute myocardial infarction. Cardiac Surgery: State of the Art Reviews
2. Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs
3. Chemical and biological heterogeneity in low molecular weight heparins: Implications for clinical use and standardization
4. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide
5. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris
6. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
7. Basic and applied pharmacology of low molecular weight heparins
8. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins
9. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor Xa activity as a pharmaceutical mechanism and a yardstick for therapy
10. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis
11. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
12. A comparison of low-molecular-weight heparin administered primarily at home with un- fractionated heparin administered in the hospital for proximal deep-vein thrombosis
13. A comparison of enoxaparin boembolism in acutely ill medical patients
14. Heparin and cancer
15. Low-molecular-weight heparin for the treatment of acute ischemic stroke
16. Low molecular weight heparin in the prophylaxis and treatment of disseminated intravascular coagulation in acute promyelocytic leukemia
17. Clinical uses of low-molecular-weight heparins
18. Fifth ACCP Consensus Conference on Antithrombotic Therapy
19. Low-molecular-weight heparins
20. Treatment options in unstable angina: A clinical update
21. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group
22. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome)
23. Low-molecular-weight heparin during instability in coronary artery disease
24. Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial
25. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
26. Fraxiparine in Ischaemic Stroke Study (FISS bis)
27. Routine heparinisation during coronary arteriography: Is it still indicated?
28. Simultaneous administration of glycoprotein IIb/IIIa inhibitors with low-molecular-weight heparins does not augment the release of tissue factor pathway inhibitor: Implications in the management of cardiovascular patients
29. Enoxaparin pharmacokinetics and pharmacodynamics after intravenous bolus administration alone and at initiation of a subcutaneous dosing regimen
30. Comparative effects of low molecular weight heparin (with and without abciximab) and unfractionated heparin on antithrombin activity during coronary angioplasty
31. Abciximab-enoxaparin interaction during percutaneous coronary intervention: Results of the NICE 1 and 4 trials
32. Abciximab and enoxaparin administration during elective high-risk PTCA in patients with more than 3 days of ticlopidine pretreatment
33. Rapid platelet function assessment using two concentrations of adenosine diphosphate after clopidogrel loading in patients undergoing cardiac catheterization
34. A randomized comparison of low-molecular-weight heparin and unfractionated heparin adjunctive to t-PA thrombolysis and aspirin (HART-II)
35. SR9010A/ORG31540, a new synthetic pentasaccharide, as an adjunct to fibrinolysis in ST-elevation acute myocardial infarction: The PENTALYSE study